RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 TECOS Finds Sitagliptin Does Not Increase Heart Failure Risk
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 28
SP 15
OP 16
DO 10.1177/1559897715611117
UL http://mdc.sagepub.com/content/15/28/15.abstract
AB TECOS was a large randomized placebo-controlled trial in patients with type 2 diabetes mellitus and cardiovascular disease, conducted to demonstrate the noninferiority of sitagliptin as compared with placebo in the risk of cardiovascular events. A prespecified secondary analysis found no impact of sitagliptin on heart failure hospitalization or related events.